Karolinska Development names new CEO
This article was originally published in Scrip
Executive Summary
The Swedish investment company, Karolinska Development, has appointed Torbjorn Bjerke as its new CEO. He will replace Conny Bogentoft, who will become the company's chief scientific officer and with responsibility for the future development of the company's portfolio. Mr Bjerke will assume his new position once a successor for his current role – CEO of the Swedish firm Orexo – has been named. Karolinska Development, which began operations in 2003, now has a portfolio of 45 companies, which span across several therapeutic areas, and 21 potential first-in-class products.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.